ClinicalTrials.gg
RecruitingNCT06691191SWAP-7Updated Nov 18, 2026

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

A Phase 4 interventional study of Ticagrelor 90 mg and Prasugrel 10 mg in Coronary Artery Disease, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Florida · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies testing prasugrel in Coronary Artery Disease — 4 open to participants now, 4 under way, 1 of them phase 3. prasugrel · Coronary Artery Disease.

Planned enrollment
32nd of 40
48 · median 84
Started
2025
with 2 others
Phase 4
23 of 40
3 open now
Registered
37th of 40
by date
Lead sponsor
8 of 40
University of Florida

Among the 40 studies testing prasugrel in Coronary Artery Disease, this one is the 32nd largest by planned enrollment, is one of 3 that started in 2025, is one of 23 in phase 4, and was the 37th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 40 studies testing prasugrel in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About prasugrel

prasugrel: first FDA approval 2009 (EFFIENT), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing prasugrel in Coronary Artery Disease, or all of them as a file.
02

Study summary

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

Read the detailed description

A strategy of P2Y12 monotherapy after 1-3 months of dual antiplatelet therapy (DAPT) is associated with a substantial reduction in bleeding events without an increase in atherothrombotic events, including in patients with acute coronary syndrome (ACS). However, different P2Y12 inhibitors vary in safety and efficacy profiles in the setting of single antiplatelet therapy (SAPT). In the TICO (Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus-eluting Stent for Acute Coronary Syndrome) trial, DAPT discontinuation at 3 months with transition to ticagrelor monotherapy was superior to standard 12-month DAPT for 1-year net adverse cardiac events in ACS patients undergoing percutaneous coronary intervention (PCI). Similarly, the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention) trial showed that in high-risk patients who have completed an initial 3-month course of DAPT following PCI, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischemic risk as compared with ticagrelor plus aspirin. In contrast, in STOPDAPT-2 ACS (Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study for the Patients With ACS), discontinuation of DAPT at 1 to 2 months after ACS PCI with transition to clopidogrel monotherapy was not noninferior to 12-month DAPT with aspirin and clopidogrel for 1-year net adverse cardiac events, due to a numerical increase in atherothrombotic events despite reduction in bleeding events. These data suggest that potent P2Y12 inhibitors should be preferred over clopidogrel in the setting of early SAPT after PCI in high-risk patients.

The ISAR-REACT (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment) 5 trial showed that in ACS patients the incidence of major cardiovascular events was lower among those who received prasugrel than among those who received ticagrelor, and the incidence of major bleeding was not significantly different between the two groups. Based on these findings, European guidelines now suggest that prasugrel should be considered in preference to ticagrelor for ACS patients who proceed to PCI. Moreover, PD studies showed that, compared with ticagrelor, prasugrel provides similar or even superior platelet inhibition [16,17]. However, this clinical PD data is in the context of using prasugrel in the context of a DAPT regimen (i.e., in adjunct to aspirin) and data on the use of prasugrel-based SAPT following PCI are limited.

Overall, these observations as well as the lack of head-to-head comparisons on the clinical and PD efficacy of ticagrelor-based and prasugrel-based SAPT underscore the importance of conducting dedicated investigations to compare these approaches. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies. Such investigation may provide insights into the safety and efficacy of these strategies and set the foundation for larger-scale investigations assessing clinical outcomes.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • percutaneous coronary intervention
  • ticagrelor
  • prasugrel
  • bleeding
  • platelets
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI.
  2. Age between 18 and 75 years old
  3. Able to provide written

Exclusion criteria

Exclusion criteria:

  1. Prior history of stent thrombosis
  2. PCI within 90 days.
  3. History of stroke/
  4. Age > 75 years old
  5. Weight \< 60 kg
  6. History of intracranial hemorrhage
  7. On treatment with any oral anticoagulant or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
  8. Patients with known coagulation disorders
  9. Known severe hepatic impairment
  10. to prasugrel or ticagrelor
  11. Pregnant and breastfeeding persons [persons of childbearing age must use reliable (i.e., oral contraceptives) while participating in the study]. If the potential subject is a person of , a pregnancy test will be done. If the subject is pregnant, participation in this study will end.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Ticagrelor monotherapy

    Ticagrelor 90 mg bid monotherapy for 21±7 days

    Drug: Ticagrelor 90 mg

  • Experimental
    Prasugrel monotherapy

    Prasugrel 10 mg qd for 21±7 days

    Drug: Prasugrel 10 mg

Interventions

  • DrugTicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.

    Also known as: Brilinta

  • DrugPrasugrelStudies of PrasugrelPrasugrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.

    Also known as: Effient

06

What researchers measure

Primary outcomes

  1. Platelet reactivity measured by VerifyNow

    The primary endpoint of the study is the comparison of P2Y12 reaction unites (PRU) levels determined by VerifyNow between prasugrel monotherapy and ticagrelor monotherapy

    Time frame: 21±7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 23 months is below that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Aug 2026 → Dec 2026 and completion Dec 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 15, 2024
StartActual
Jan 8, 2025
Primary completionEst.
Dec 31, 2026was Aug 2026
CompletionEst.
Apr 30, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Dec 31, 2026
Nov 18, 2026
Study completion
Dec 31, 2026→Apr 30, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Aug 31, 2026→Dec 31, 2026
    Study completion Dec 31, 2026→Apr 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06691191
Responsible party
Sponsor
First posted
Nov 15, 2024
Start date
Jan 8, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Francesco Franchi, MD
Contact
francesco.franchi@jax.ufl.edu
9042445515
Andrea Burton
Contact
andrea.burton@jax.ufl.edu
(904) 244-5617
Francesco Franchi, MD
principal investigator · University of Florida College of Medicine Jacksonville

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prasugrel

Start the discussion